• 1.

    Tan JA, et al. Mortality in ANCA-associated vasculitis: A meta-analysis of observational studies. Ann Rheum Dis 2017; 76:15661574.

  • 2.

    Robson J, et al. Damage in the ANCA-associated vasculitides: Long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis 2015; 74:177184.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Robson JC, et al. Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatol Int 2018; 38:675682.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Jayne DRW, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 2017; 28:27562767.

  • 5.

    Pepper RJ, et al. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis [published online ahead of print Sep 18, 2018]. Rheumatology (Oxford) doi: 10.1093/rheumatology/key288.

    • Search Google Scholar
    • Export Citation
  • 6.

    McAdoo SP, et al. Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. Nephrol Dial Transplant 2018; 33:899.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 7.

    Cortazar FB, et al. Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis. Kidney Int Rep 2018; 3:394402.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Furuta S, et al. Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): Protocol for a multicentre, open-label, randomised controlled trial. BMJ Open 2017; 7:e018748.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Touma Z, Gladman DD. Current and future therapies for SLE: Obstacles and recommendations for the development of novel treatments. Lupus Sci Med 2017; 4:e000239.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Houssiau FA, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69:6164.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 11.

    Ruiz-Irastorza G, et al. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev 2017; 16:826832.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Condon MB, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013; 72:12801286.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 13.

    Rovin BH, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis [published online ahead of print Nov 5, 2018]. Kidney Int doi: 10.1016/j.kint.2018.08.025.

    • Search Google Scholar
    • Export Citation
  • 14.

    Holden NJ, et al. ANCA-stimulated neutrophils release BLyS and promote B cell survival: A clinically relevant cellular process. Ann Rheum Dis 2011; 70:22292233.

    • Crossref
    • Search Google Scholar
    • Export Citation

Targeting Inflammation in Autoimmune Kidney Diseases

  • 1 Andreas Kronbichler, MD, and Gert Mayer, MD, are associated with the Department of Internal Medicine IV (Nephrology and Hypertension), Innsbruck, Austria.
Restricted access
Save